Pelthos Therapeutics Inc.
For the period ended Dec 31, 2024. Filed Mar 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 27, 2025
PTHS$9.37+0.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| Years Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| OPERATING EXPENSES | ||
| General and administrative expenses | $4,110,045 | $2,738,948 |
| Research and development | 1,179,436 | 2,579,418 |
| Professional fees | 2,281,968 | 1,543,918 |
| Total operating expenses | 7,571,449 | 6,862,284 |
| NET LOSS FROM OPERATIONS | (7,571,449) | (6,862,284) |
| OTHER (EXPENSE) INCOME | ||
| Interest expense | (786,393) | (518,509) |
| Other income | 39,413 | — |
| Gain on default judgement | 363,091 | — |
| Total other (expense) income | (383,091) | (518,509) |
| Net loss before provision for income taxes | (7,955,338) | (7,380,793) |
| Provision for income taxes | — | — |
| NET LOSS | $(7,955,338) | $(7,380,793) |
| Net loss per common share - basic and diluted | $(1.43) | $(5.78) |
| Weighted average number of common shares outstanding during the year - basic and diluted | 5,574,473 | 1,276,543 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.